Further details on the call and application process will follow shortly
patients must request pricing through their prescribing provider or telehealth platform
Later-stage evaluation continues under the TRIUMPH programme
Selected-variant lyophilized material in a sealed, labeled vial (choose mg option from variants) Access to lot-specific Certificate of Analysis (COA) via the COA portal Analytical documentation (e.g., HPLC/MS) when available for the batch AOD-9604 is studied in receptor pharmacology and signaling characterization workflows using controlled laboratory assay systems: Receptor interaction studies: Investigated using receptor-expressing platforms to characterize binding and functional activity under controlled conditions
The emergence of GLP-1 as a modulator of reward, stress, inflammation, and metabolic function represents a promising frontier in addiction medicine
In summary, based on preclinical and clinical studies, the addition of a dual GLP-1/GIP receptor agonist like CT-868 to insulin therapy for the treatment of T1D in patients with overweight or obesity could offer significant benefits in terms of improved glycemic control, reduced insulin doses, and weight loss, while also likely having a favorable safety and tolerability profile due to its intentional signaling bias
